At Pandion Therapeutics we are creating innovative modular proteins, antibodies and bispecifics precisely engineered to achieve lasting therapeutic outcomes for autoimmune and inflammatory diseases.
We design and develop therapeutics with a modular approach to rebalance the immune system through differentiated mechanisms of action that can act systemically or locally. With our technology, know-how and drug development expertise, Pandion takes a unique combinatorial approach to developing immunomodulators that can be paired with tissue-selective tethers to create precisely engineered therapeutics. This approach has resulted in an accelerated pipeline of candidates for autoimmune and inflammatory diseases that we are advancing to the clinic.
Pandion is built on strong science and drug development expertise, and our passionate team is committed to advancing new drugs for patients. We are backed by leading life sciences investors including Polaris Partners, Versant Ventures, Roche Venture Fund, SR One, BioInnovation Capital, and the JDRF T1D Fund.